Lyell Immunopharma Inc (LYEL) — Capital Reinvestment Ratio

Latest as of December 2019: 0.41x

Lyell Immunopharma Inc (LYEL) has a Capital Reinvestment Ratio of 0.41x as of December 2019, meaning it reinvests 0% of its operating cash flow ($39.47 Million) in capital expenditures ($16.05 Million). See Lyell Immunopharma Inc (LYEL) net asset quality to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

0.41x
Capex / Operating Cash Flow

Operating Cash Flow

$39.47 Million
USD

Capital Expenditures

$16.05 Million
USD

Data as of

Dec 2019
Most recent filing

Lyell Immunopharma Inc Capital Reinvestment Ratio (2019–2019)

This chart tracks Lyell Immunopharma Inc's Capital Reinvestment Ratio across 1 annual periods. Check cash flow reinvestment rate of Lyell Immunopharma Inc to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for Lyell Immunopharma Inc (2019–2019)

Year-by-year Capital Reinvestment Ratio for Lyell Immunopharma Inc from 2019 to 2019. For live market cap and broader valuation context, see market cap of Lyell Immunopharma Inc.

Year Reinvestment Ratio Operating CF (USD) Capital Expenditures YoY Change
2019 0.41x $39.47 Million $16.05 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow